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 This research paper investigated the performance of the supply chain system in 
the pharmaceutical industry in Pakistan. The study was based on the hypothesis that the 
adopted supply chain systems lack proper structures to deal with the challenges of the 
business environment in which they operate, and as such were underperforming. 
Therefore, the objective was to ascertain the nature and the dynamics of the SCM 
(Supply Chain Management) system used in the drug industry. The objectives of the 
research were anchored on three factors that include Supply Chain Flexibility/Agility 
Performance, Supply Chain Resource Performance, and Supply Chain Output 
Performance. These three metrics were used to describe the independent variable which 
comprises the supply chain performance of Pakistan’s pharmaceutical industry. The 
research data was collected through questionnaires that would make it possible to analyze 
and interpret information gathered. 
The questions were administered to a sample of the players that represent every 
sector of the industry (multinationals, local manufacturers, retailers, and regulators). The 
final results of the study support or discourage the hypotheses that 1) Manufacturers 
struggle to manage lead-time as a result of factors such as government. 2) Manufacturers 
lack satisfactory levels of performance in terms of Supply Chain Flexibility/Agility 






  Pakistan became an independent country in 1947 and a few decades ago 
established its own pharmaceutical industry supply chain framework. Beginning with 
approximately twenty pharmaceutical operating and production units that manufactured 
finished dosage drug forms and supplied active drug ingredients to their peers in the local 
and international market, the country now has hundreds of such units. This serves as 
evidence to the notion that the size of the country’s pharmaceutical industry’s supply 
chain framework has grown considerably. It makes sense for the government and the 
industry’s stakeholders to invent and implement new ways to revitalize the country’s 
pharmaceutical industry so that it can post significant improvements in productivity, 
efficiency, ethics, and profitability (Ahmed & Jalees, 2008). 
One of the methods in which analysts describe and evaluate the performance of an 
industry, or even that of an individual organization within the industry in question, was to 
look at the volume of trade in terms of processing and exchanging goods and services 
within and outside the said industry. Pakistan’s pharmaceutical industry was one of the 
fastest growing industries in the territory of emerging economies. Between the years 
2014 and 2015, its pharmaceutical industry managed to reach $212 million in export 
turnover (Business Mirror, 2016). This was still small compared to the export turnover 
values that were being posted by Western, European and Asian countries that already had 
a mature pharmaceutical industry supply chain. This disparity suggests that there are 
numerous improvements that the government and the members of the private sector could 
make in order to make the pharmaceutical industry and the underlying supply chain 
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framework that supports it more globally competitive and productive (Ahmed & Jalees, 
2008).      
Supply Chain Flexibility was one of the key variables that was examined in the 
paper. Supply Chain Management can be a complex and at the same time volatile 
process. The unpredictability of both the internal and external supply chain variables can 
have a significant impact on the outcomes of an entire industry, or in this case, Pakistan’s 
pharmaceutical industry. The assumption was that the more flexible a supply chain 
framework for the pharmaceutical industry is, the more resilient it would be when facing 
external and internal shocks. Resource and Output Performance are variables that focused 
on the internal management of an industry’s supply chain network. The stability of on-
time deliveries, quality control measures and the overall success of the flow of goods and 
services from one end of the supply chain network to another were examples of the 
processes involved in Resource and Output Performance. Generally, a supply chain 
framework that had a more stable Resource and Output Performance was a more valuable 
one. Additionally, Resource and Output Performance weakness could add to the 
volatilities and uncertainties in the management of an industry’s supply chain network. In 
an ideal scenario, both the levels of Supply Chain Flexibility and Resource and Output 
Performance should hover consistently at an optimum performance level in order to 
ensure the successful delivery of goods and services from the initial to the end of the 
network.   
Problem Statement 
Supply chain management performance of the pharmaceutical industry in 
Pakistan was not up to par with the global average. At present, Pakistan’s pharmaceutical 
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industry’s supply chain framework still relies on old technologies in relation to drug 
discovery and development models. Some pharmaceutical firms in the country have been 
implementing more modern methods than the others, but the quality and precision of this 
execution is still questionable. It was worth noting these problems and limitations are not 
uncommon and therefore should only be expected from a still developing industry such 
as the one being discussed in this paper (Business Mirror, 2016).    
Significance of the Research 
The significance of the research is to conclude whether there is an actual need for 
the supply chain management performance of Pakistan’s pharmaceutical industry to 
improve or otherwise. This paper aimed to suggest that the supply chain performance in 
Pakistan’s pharmaceutical industry is weak and can benefit from further improvements. 
This study indicated areas where supply chain management could be improved and could 
benefit pharmaceutical companies. In general, improvements in Pakistan’s 
pharmaceutical industry’s SCM processes would benefit the patients, medical and 
healthcare professionals, medical and healthcare business organizations, the entire 
pharmaceutical industry, and eventually, Pakistan’s economy. 
Purpose of the Research 
The purpose of the study was to ascertain the perceptions of industry 
professionals regarding agility/flexibility performance, resource performance, and output 
performance of supply chain management of the pharmaceutical industry in Pakistan. An 
attempt was then made to apply this additional information from the field in order to 
effect improvement in the supply chain management of pharmaceutical industry in 
Pakistan. Based on the objective of the study to ascertain the nature and the dynamics of 
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the SCM systems used in the drug industry, data collection was focused on three factors, 
namely supply chain flexibility or agility performance, resource performance, and output 
performance. Collection of data was achieved through questionnaires that provide 
standardized responses that could be compiled for qualitative and quantitative analysis. 
The purpose was to determine whether the Pakistani pharmaceutical industry’s supply 
chain performance is indeed struggling.  The type of data that was collected was 
responses from a sample population of 60 Pakistani pharmaceutical firm employees, 
using a customized questionnaire.     
Research Questions 
The independent variable was the supply chain performance of Pakistan’s 
pharmaceutical industry. The dependent variable, on the other hand, was the perceptions 
of industry professional in Pakistan’s pharmaceutical industry.  This means there are two 
negatively performing sectors here: Pakistan’s pharmaceutical industry and Pakistan’s 
pharmaceutical industry supply chain network.  
The research questions associated with the study were as follows:  
1. Do pharmaceutical industry professionals in Pakistan perceive growth is restricted 
by inadequacies in the SCM (Supply Chain Management) models used by the 
industry participants in Pakistan? 
2. Do pharmaceutical industry professionals in Pakistan perceive Pakistan’s 
pharmaceutical industry supply chain performance is underperforming? 
3. Do pharmaceutical industry professionals in Pakistan perceive a problem 
regarding flexibility and agility in supply chain performance of the 
pharmaceutical industry in Pakistan? 
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4. Do pharmaceutical industry professionals in Pakistan perceive a problem 
regarding resource performance in the supply chain management of the 
pharmaceutical industry in Pakistan? 
5. Do pharmaceutical industry professionals in Pakistan perceive a problem 
regarding output performance in the supply chain performance of the 
pharmaceutical industry in Pakistan?          
Assumptions 
 The assumptions of this study were as follows: 
1. The key assumption in this study was anchored on the discussion that was already 
covered in the Research Questions and Hypothesis section.  
2. It was also assumed that the pharmaceutical industry’s SCM practices play an 
integral role in maintaining a fully functional pharmaceutical industry.  
3. In terms of the sampling techniques and procedures, it was assumed that the 
chosen samples will be representative of the target population (i.e. professionals 
within the pharmaceutical industry). 
Limitations  
 The limitations of this study were as follows: 
1. The major limitation of this study was that it will not cover factors relating to 
global market dynamics that affect the pharmaceutical industry in general.  
2. Only a small sample population size of 60 was used in the study. 
Delimitations 
 The delimitations of this study were as follows: 
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1. The study was delimited to focus only on the pharmaceutical industry and its 
supply chain performance. Although general supply chain management and 
performance concepts were used, its application in the Pakistani pharmaceutical 
industry was prioritized.  
2. This limitation was intentional in that this paper focused on the relationship 
between supply chain performance and the state of the Pharmaceutical Industry in 
Pakistan, using responses from the sampling population of 60 Pakistani 
pharmaceutical industry employees. The actual global pharmaceutical industry, 
however, has been included in the discussions.     
Definition of Terms 
1. Supply Chain Performance - Refers to how well an organization manages its lead 
time, working capital, and inventory in realizing strategic production, profits, and 
market goals. 
2. Supply Chain Management - Refers to the collection of practices that are related 
to an industry’s Supply Chain Network. 
3. Pakistan’s Pharmaceutical Industry - Refers to all the participants in Pakistan’s 
pharmaceutical industry supply chain, a collection of firms, businesses, and 
corporations 
4. Supply Chain Flexibility/Agility Performance - Refers to how flexible or agile an 
industry’s supply chain framework in terms of adapting to changes, new trends, 
and volatilities (e.g. breakdowns, supply disruptions). 
5. Supply Chain Resource Performance - Paints an overall picture of how the key 
processes within the supply chain system are being processed, and how the 
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sample population perceives them in terms of profitability, productivity, and 
efficiency. 
6. Supply Chain Output Performance - Paints an overall picture of how outcomes are 
presented by an industry’s supply chain framework as a whole, addresses aspects 







































Review of Literature 
 
Pakistan’s pharmaceutical industry is growing at a very fast rate (Zaman, 2011). 
There is an ongoing trend that suggests that companies that focus on adapting to the 
continuously changing consumer behaviors are going to continue to dominate the 
industry (Khalique, Shaari, Abdul, Isa, & Ageel, 2012). This is the same model that other 
more developed national level pharmaceutical industries have been following and if that 
is to be used as a basis, then it would be safe to suggest that Pakistan’s pharmaceutical 
industry would also have the same outcome (Zaman, 2011).   
Just like any other industry that is dominated by the private sector, the Pakistani 
pharmaceutical industry is dependent on various variables. Generally, these are variables 
that can be categorized as political, economic, or social (Malik & Kotabe, 2009). These 
variables can be used as determinants or even predictors of the future state of the 
country’s private sector dominated industries, one of which is the pharmaceutical 
industry. Among the three broad categories of private sector led industry variables and 
predictors, the ones that are related to the country’s economy (i.e. economic variables) 
have had the biggest impacts on the pharmaceutical industry and its supply chain 
framework’s performance (Malik & Kotabe, 2009).   
Pakistan’s economy has been suffering as a result of the numerous geopolitical 
conflicts that its government has been involved in (Cohen, 2002). The wars that the 
country has waged against terrorism, for example, pose major economic risks that the 
country’s government is yet to fully resolve (Cohen, 2002). It has been established in 
previous studies that the presence and persistence of geopolitical events such as war and 
widespread terrorism have a negative overall impact on the economy (Bilgin & Morton, 
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2002). An economy that is hindered by these negative risks can never grow to its full 
potential, especially when compared to regional and international peers that are not 
subject to the outcomes of wars and other geopolitical conflicts. The country’s 
pharmaceutical industry is one of the many private sectors led industries at risk of being 
disrupted as a result of this longstanding problematic geopolitical situation. (Bilgin & 
Morton, 2002). 
Aside from geopolitical conflicts and risks, Pakistan’s economy has also shown 
signs of uncontrollable domestic inflation, a slow rate of gross domestic product and 
overall economic growth, and the substantial devaluation of the national currency relative 
to its regional peers and the most heavily traded basket currencies such as the Dollar, 
Euro, Pound, and Yen (Ali, Rehman, Yilmaz, Khan, & Afzal, 2010). There is little to no 
doubt that the government is taking real steps to come out of this challenging situation, 
but the question is whether it has been enough to uplift the economy? (Ali, Rehman, 
Yilmaz, Khan, & Afzal, 2010). Discussing the economy is relevant in the case of 
Pakistan’s pharmaceutical industry in that a healthy and fully functioning economy is one 
that can support the growth of private sector led industries such as the pharmaceutical 
industry, including all of the firms that operate within it and the ones that are connected 
to it via the complex pharmaceutical industry’s supply chain framework (Shah, 2004).   
According to a Market Realist report that cited Moody’s article on the global 
pharmaceutical industry, the  industry-wide outlook has been changed from positive to 
stable, referencing the continuous strengthening of the U.S. Dollar, the rising costs of 
research and development, and the lower levels of pricing flexibility that eventually has 
eaten away a significant portion of the pharmaceutical firms’ profitability as some of the 
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major risks  have been exposed (Dabney, 2016). Currently, the global pharmaceutical 
industry is worth $1.072 Trillion in terms of revenues, making it one of the most lucrative 
and at the same time, integral industries worldwide (Statista, 2017). From a long-term 
perspective, analysts expect the industry to grow at an annual rate of 8%. When it comes 
to industry revenue and market share, Pakistan lags behind its peers in the west and the 
Pacific, namely the United States, the European Union, and Japan, which controls 48%, 
28%, and 12% of the total world pharmaceutical market respectively (Statista, 2017).                      
Stakeholder Analysis of Pakistan’s Pharmaceutical Industry 
Patients. Using the pattern that was developed by developed countries with a 
well-developed healthcare sector (e.g. the United States, Canada, and Scandinavian 
Countries), it would be safe to suggest that accessibility, affordability, and the quality of 
the products and services being offered are the top three concerns. A good case in point 
would be the United States’ Affordable Care Act which highlights the targeted 
improvements on these three aspects of healthcare. This is arguably the same pattern that 
emerging countries like Pakistan are trying to follow. What the implementation of this 
model creates is a medical and healthcare environment that benefits the patients or in the 
case of the pharmaceutical industry’s supply chain network, the end-users or consumers 
of the drugs and pharma products.  
Medical and healthcare professionals. An improvement in the overall quality 
and performance of Pakistan’s pharmaceutical industry’s supply chain will generally 
make it easier for medical and healthcare professionals to do their job. Drug-related 
treatment regimens are particularly common in medical and healthcare practice (Schouten 
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et al., 2011) and so a sufficient access to affordable drugs and pharmaceutical products 
can have a significant impact on the way these professionals do their jobs.  
Medical and Healthcare Businesses and Organizations. Medical and 
healthcare businesses and organizations that would benefit from improvements in the 
performance of Pakistan’s pharmaceutical industry include hospitals, clinics, medical 
centers, and the pharmaceutical firms that sell drugs, drug precursors, and other raw 
materials. By stimulating improvements in the country’s pharmaceutical industry’s 
supply chain performance, organizations like hospitals would be in a much better 
financial and operational position to fulfill their mandates to provide efficient, high 
quality, affordable, and accessible medical and healthcare services to those who need it, 
i.e. patients. From a purely financial perspective, they would be in a better position to cut 
their costs and magnify their bottom line, among other aspects of profitability.            
Pakistan’s pharmaceutical industry. By improving the pharmaceutical 
industry’s supply chain performance in Pakistan, the industry that is going to benefit 
would naturally be the pharmaceutical industry. This can happen as a result of a complex 
interplay of factors, but in most cases, such outcomes can be attributed to more cost 
efficient and productive operations, which in turn leads to lower operating costs and 
therefore higher profit margins. The higher profit margins can then be used by the 
pharmaceutical industry firms to improve the quality of their products through research 
and development projects. By keeping the firms that power the country’s pharmaceutical 
industry profitable, their long-term growth and development can be secured and sustained 
(Itami & Nishino, 2010). 
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Pakistan’s Economy. The ultimate beneficiary of all the positive effects of an 
improved pharmaceutical industry supply chain performance would be Pakistan’s 
economy. A healthy population (which is thanks to more optimized access to drugs and 
pharma products) would mean lower national health and medical services-related 
expenditures for the government (Warnecke et al., 2008). This can contribute 
significantly to the country’s economic growth. A healthier and more profitable 
environment for businesses and organizations operating in the pharmaceutical industry 
would stimulate more investments, expansion, and job creation. Combined, these would 
create a snowballing effect that would contribute to the sustained growth of Pakistan’s 
economy.   
How the Pharmaceutical Industry Supply Chain Network Works   
Pakistan’s national pharmaceutical industry shows a lot of promise but there are a 
lot of steps that need to be taken in order for it to be truly competitive regional industry 
leader, and one of those steps is the liberalization and enhancement of its supply chain 
management performance (Usman, Raouf, Ahmad, & Sparks, 2009; Nadvi & Halder, 
2005). There are more than six hundred companies that operate in Pakistan. The exact 
number is hard to determine because it tends to fluctuate with an upward bias from time 
to time. It is worthy to note that more than half of the pharmaceutical firms that have 
been established in the country are operating units (Usman, Raouf, Ahmad, & Sparks, 
2009; Nadvi & Halder, 2005). 
An operating unit is not a standalone pharmaceutical industry corporation like 
Pfizer, Johnson and Johnson, and GlaxoSmithKline (GSK). Rather, it is a larger part of a 
pharmaceutical production firm, which in turn, may just be one of the many components 
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of a pharmaceutical industry giant. An operating unit is the main functional component of 
the pharmaceutical industry’s supply chain framework (Khan, 2012). In order to 
understand the role that an operating unit plays in the supply chain framework and the 
corresponding performance of pharmaceutical firms, one has to have a decent knowledge 
of the pharmaceutical manufacturing process. From a linear perspective, there are 
different processes involved in the industrial and mass production and synthesis of drugs 
and pharmaceutical products, each of which has to be fittingly integrated to ensure an 
optimum SCM performance (Shah, 2004).  
Because of the complexity of the entire process and the sheer volume of materials 
that have to be transformed during the operation, a per unit type of operation has been 
developed. Under this type of scheme, each unit would be responsible for its own series 
of operations (Koh, Schuster, Chackrabarti, & Bellman, 2003). There are, for example, 
pharmaceutical operating units that take care of the milling, coating, granulation, dosage, 
and tablet pressing (among other methods of containment), and extrusion. Depending on 
the type of drug or pharmaceutical product that is being developed, certain operating 
units (each with its own specialty) can be added or removed from the supply chain 
framework. This is, of course, meant to optimize the entire process and to ensure that 
each operating unit would have an efficient level of utilization (Koh, Schuster, 
Chackrabarti, & Bellman, 2003).   
The five types of operating units in the pharmaceutical industry are the following: 
pre-formulation development, formulation development, power blending, milling, 
granulation, and hot melt extrusion (Wilson, Williams, Jones, & Andrews, 2012). 
Focusing again on Pakistan, most of the pharmaceutical operating units in the country are 
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wholly or partially owned subsidiaries of international pharmaceutical firms (Khan, 
2012). This is why the economic and geopolitical fluctuations in the country have 
severely affected the growth and expansion of the pharmaceutical industry. A significant 
change in the rate of inflation and foreign exchange rate and currency value would 
normally lead to supply chain disruptions because of the cost-related effects on the way 
the operating units get funding from and ship their outputs to their parent firms or other 
operating units for further processing (Dabney, 2016). In the end, this is going to have a 
significant effect on the companies’ operating margins. Regardless of how prosperous the 
future of the pharmaceutical industry in Pakistan is, there is little to no choice that such a 
picture of the future would be realized, if even the smallest industry supply chain units 
(i.e. the unit operators) cannot generate a level of profit that is attractive enough for them 
to consider significantly expanding their operations (Khan, 2012).   
The pharmaceutical industry in Pakistan is still changing. From a supply chain 
management perspective, the country is becoming more and more competent when it 
comes to establishing its own supply chain network in as far as pharmaceutical product 
development and manufacturing are concerned (Ali & Akram, 2012). This may be due to 
the fact that the country has learned a lot of lessons during the closing decade of the 
twentieth century. It can be recalled that during that time, the largest portion of Pakistan’s 
pharmaceutical industry was controlled by multinational corporations. Nearly two 
decades later, the ratio between multinational corporations and Pakistani-owned and 
operated companies have dramatically changed. Of the numerous pharmaceutical 
operating units in the country, more than half (55%) are Pakistani owned and operated, 
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while slightly less than half (45%) are owned and operated by multinational corporations 
(Zaman, 2011).  
This is a positive type of development because this means that the country is 
starting to get a bigger share of the thriving pharmaceutical industry; this can later be 
used as a leverage to encourage more pharmaceutical firms to be established and for 
existing ones to expand (Malik & Kotabe, 2009). In theory, that would lead to better 
prospects when it comes to government corporate tax revenue collection and job creation. 
A bigger local pharmaceutical industry is also going to create a boom in the 
establishment of new and existing pharmaceutical industry support firms (Ali & Akram, 
2012). These support firms are generally businesses that are indirectly related to the 
pharmaceutical industry. Examples of these businesses would include those that supply 
the different components or raw materials that the individual pharmaceutical units use in 
their respective operations (Gunasekaran & Ngai, 2005).  Pharmaceutical marketing and 
advertising firms could be included in this sector.  
It is worth noting that all of these firms, regardless of whether they are directly or 
indirectly related to the process of manufacturing drugs and other pharmaceutical 
products, are still considered a part of the overall pharmaceutical industry supply chain 
framework. To be more specific, these support businesses serve as the upstream business 
partners of the actual firms that manufacture the drugs and pharmaceutical products that 
eventually get sold to the end users, e.g. patients with the target diseases (Giunipero & 
Eltantawy, 2004). From the perspective of the support businesses, on the other hand, the 
actual firms that manufacture the drugs and pharmaceutical products would serve as their 
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downstream customers in a typical business transaction where their clients are not the end 
users but industry-related businesses (Zaman, 2011).   
In Pakistan, despite the improvements that were made and realized in the 
pharmaceutical industry, a lot of challenges are left unaddressed. For example, the local 
pharmaceutical industry can only supply around four-fifths percent of the total demand 
for drugs and other pharmaceutical products; the remaining twenty percent have to be 
imported from countries like China, the United States, Japan, and Europe (Zaman, 2011). 
Otherwise, there would be a deficit in the industry’s supply chain, which is common 
among developing countries because they have no choice but to import the raw materials 
that they do not have access to or are not capable of producing (Sattar & Maqsood, 2003). 
This is a risk that can potentially lead to supply shortages of the end-user products (e.g. 
the drugs and pharma products) and so the country and the local industry cannot afford to 
scrimp on the imports. The process of importation, in itself, can still be considered a 
supply chain related process, only it is more complicated because an external source is 
being used to supply the local needs of Pakistan’s pharmaceutical industry (Sattar & 
Maqsood, 2003).    
One of the biggest challenges that Pakistan’s Pharmaceutical Industry’s supply 
chain framework still struggles to solve is the excessively high levels of government 
influence and in some cases, even total control, on the prices of pharmaceutical products, 
even those that are imported into the country by multinational corporations, which is also 
common in other industries and in other emerging countries (Fogel, 2006). This leads to 
the next major challenge on the country’s pharmaceutical industry supply chain, the 
continuous reliance on imports of end products and raw and precursor materials.  
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This highlights the potentially negative impacts of high levels of inflation and 
foreign exchange rate fluctuations on the growth and stability of the pharmaceutical 
industry’s supply chain. For example, the foreign exchange rate fluctuation, which is 
biased towards the devaluation of the Pakistani Rupee and against other major and 
heavily traded currencies makes it more expensive for local operating units 
(pharmaceutical firm subsidiaries) to import their raw materials and other precursors 
from China and other markets that are part of the industry’s supply chain framework 
(Dabney, 2016). Although a continuously increasing percentage of the operating units in 
the pharmaceutical industry is being owned and operated by Pakistani nationals, this does 
not change the fact that they still have to import raw materials and precursors from 
foreign markets. This is because the upstream supply chain network in Pakistan for 
pharmaceutical products is still not well established (Zaman, 2011). It still relies on 
foreign imports. This, therefore, presents a major supply chain challenge that the 
government, ideally in partnership with the private sector, should address, but for some 
reason, it has not (Zaman, 2011). 
Another major limitation to the continuous growth and expansion of the country’s 
pharmaceutical industry is the increasing costs of drug production (Zaidi, Bigdeli, Aleem, 
& Rashidian, 2013). This may be due to the upward changes in wages, energy costs, 
Research and Development, and other variable expenses. In general, these changes make 
the idea of setting up a pharmaceutical firm or subsidiary in Pakistan less attractive 
(Zaidi, Bigdeli, Aleem, & Rashidian, 2013).    
Perhaps the biggest challenge that the nationwide pharmaceutical industry is 
facing is the lack of sufficient initiatives that is aimed at improving the pharmaceutical 
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firms’ access to the local and international markets (Khalique, Shaari, Abdul, Isa, & 
Ageel, 2012). Based on the nature of this challenge, this is essentially a supply chain 
management related problem. So far, the pharmaceutical operating units in Pakistan are 
engaged in pre-contracted deals with their parent companies. This means that the only 
pharmaceutical industry participants that are being attracted to set up shop in Pakistan are 
those that already have a connection with other local and multinational firms (Shabbir, 
n.d.).   
Pharmaceutical startups are fairly rare in the country; if there are any, very few 
succeed in generating profits because of the highly restrictive business environment for 
pharmaceutical firms, especially the smaller ones (Shabbir, n.d.). This can again be 
attributed to the fact that the individual components or clusters within the pharmaceutical 
industry’s supply chain framework are not well integrated. This, in theory, makes it hard 
for a company who wants to address the supply deficits and gaps in a certain aspect of 
drug manufacturing (e.g. pre-formulation and formulation drug requirements, among 
others) to supply other businesses because of the lack of linearity and standardization in 
the process (Wilson, Williams, Jones, & Andrews, 2012).   
This challenge in Pakistan’s pharmaceutical industry’s supply chain framework 
may also be attributed to the political instability and continuously deteriorating law and 
order situation in the country. Markets and the customers in those markets are rarely 
willing to have unrestricted access to trade and other transactions that involve sales if the 
political, social, and economic environments are not conducive enough (Fogel, 2006). 
Pakistanis lagging in terms of the establishment of an orderly government and a social 
and economic environment where pharmaceutical firms can thrive by having complete 
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and unimpeded access to both the local and international markets for their output 
products. This applies to all four types of drug manufacturing companies (based on the 
diverse types of drug manufacturing licenses available) that operate in the country: 
formulation, basic manufacturing, semi-basic manufacturing, and repacking. In almost all 
cases, the problems that these four types of pharmaceutical firms encounter in Pakistan 
can be addressed by an unimpeded and a higher level of market access. In a study 
published in the International Journal of Business and Information Technology (2011), a 
group of researchers suggested that a new wave of information technology-based 
marketing and supply chain management strategies could significantly help address the 
problematic Pakistani pharmaceutical industry situation. Some examples of the 
interventions that was proposed in that study include the use of digital media and 
electronic commerce, more intensive studies and understanding of consumer behavior, 
and an increase in the level of focus on highly specialized drugs (Aamir & Zaman, 2011). 
The Global Pharmaceutical Industry 
The global pharmaceutical industry is perhaps one of the most complex and 
research-intensive industries. This is because innovation has long served as the backbone 
and the foundation that has been powering up this industry (Dunlap, Kotabe, & 
Mudambi, 2010). Some of the most common examples of companies and firms that 
operate in the pharmaceutical industry include independent drug and drug services 
research and development firms, drug manufacturers, and developers of medical and 
healthcare devices. The goal of the pharmaceutical industry, at large, is to lead the 
discovery, development, production, and marketing processes in relation to drugs and 
other products that can be used as and for medication (Kolb & Sharpless, 2003). It is 
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worth noting that while the pharmaceutical industry has its own internal checking and 
balancing measures, it is still subject to the often harsh scrutiny of the government 
regulatory agencies. This is the case since faulty and improperly monitored and regulated 
drugs, medications, and other pharmaceutical products, just like food, can have an 
adverse effect on the health of entire populations. Such types of adverse effects, as a 
result of policy miscalculations, can lead to the generation of unnecessary costs for the 
government (Dunlap, Kotabe, & Mudambi, 2010). Mishaps in the pharmaceutical 
industry are not that uncommon and so far, the government, especially those that are in 
developing countries, have already learned their lesson about the importance of 
subjecting the pharmaceutical industry to heavy scrutiny. This is the main reason that it is 
now subject to a highly diverse set of regulations, laws, and policies. Some of the 
processes that government agencies, departments, and authorities tend to pay particular 
attention to include patenting, new drug development, testing, licensing, and marketing 
(Dunlap, Kotabe, & Mudambi, 2010).   
There are numerous ways in which drugs and other pharmaceutical products can 
be allowed or not allowed to enter the market. A review of the recent trends would show 
that the regulations which the pharmaceutical firms and the broader pharmaceutical 
industry face are increasing both in terms of number and individual complexity. This can 
be considered as a double-edged sword, mainly because it (the trend) can affect both the 
very people that the laws and regulations are trying to protect and the organizations that it 
is trying to restrict, both in positive and negative ways (Guler & Nerkar, 2012). As an 
example, pharmaceutical firms get positively affected by the heavy regulation schemes 
being implemented by the government because it practically forces them to innovate and 
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remain competitive; the people who are the target consumers of a newly developed drugs, 
on the other hand, would benefit from the access to safe, effective, and affordable drugs 
for medication purposes. Focusing on the negative side, on the other hand, the increasing 
level of laws and regulations that the government imposes on pharmaceutical firms 
makes it harder for companies that develop drugs and medical devices to provide much-
needed products and services for people who need it (Guler & Nerkar, 2012). Patients 
with medical conditions that are harder to treat, for example, would find it more difficult 
to procure needed medicines because of the difficulty of the companies that are 
developing the drugs and medical devices to be granted the access to their target markets. 
From an economic perspective, this creates a deficit situation where the population of 
people whose medical and healthcare needs fail to be satisfied significantly increases. 
This only goes to show that the process of regulating the pharmaceutical industry can 
work both ways (Itami & Nishino, 2010). 
Key Processes Involved in the Pharmaceutical Industry’s Supply Chain Framework 
Drugs can easily be identified as the staple products being offered by firms 
operating in the pharmaceutical industry. Drugs share both homogeneous and 
heterogeneous economic qualities in that all types of drugs can be considered drugs but 
not all drugs are of the same type. Every few years, more types and classes of drugs are 
being discovered. After being discovered, it only takes a short period of time before they 
can be fully developed and released into the market, depending on the applicable 
regulatory frameworks and the actual need or demand for the product. Focusing on the 
marketing of new drugs, there are two key requisite processes that likely all 
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pharmaceutical industry firms have to go through, drug discovery and drug development 
(Shabbir, n.d.).   
To be able to answer the questions that are related to the supply chain 
management framework performance in the pharmaceutical industry in Pakistan, it is 
important to have a solid understanding of the different processes involved in the delivery 
of pharmaceutical products (e.g. drugs) to consumers, ideally from the start to end (Zaidi, 
Bigdeli, Aleem, & Rashidian, 2013). In most cases, it starts from the first phases of drug 
discovery, where a lead compound gets generated or discovered, and ends with the last 
stage of the drug development process, where marketing applications for various 
countries and manufacturers get the approval they need in order to be cleared for actual 
selling (Koh, Schuster, Chackrabarti, & Bellman, 2003). 
In a study that was published in the International Journal of Pharmaceutical and 
Healthcare Marketing, a group of researchers examined the possibility of developing and 
implementing a service quality scale that could measure the service quality of an entire 
pharmaceutical industry supply chain framework (Ahmad, Usman, Raouf, & Sparks, 
2009). In order to do this, the researchers studied the cases of 413 pharmaceutical 
retailers working in two of the biggest cities in Pakistan. What they came up with was a 
ten-item survey scale that focuses on four supply chain performance dimensions 
primarily for the pharmaceutical industry. The goal, of course, was to ensure that the 
questionnaire that would be created based on the model that they developed would not 
only be valid but, also reliable. Based on the study that they conducted, tangibility, 
reliability, responsiveness, adaptability, assurance, and empathy, are among the most 
important variables. In the end, they concluded that despite the abundance of studies that 
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suggest a diverse combination of dimensions or variables that can be incorporated in the 
process of evaluating supply chain management performance, there should not be a 
strictly universal set of dimensions and or items that can be used to determine service 
quality across a section of service industries, or in this case, the supply chain performance 
of a target country’s (Pakistan) pharmaceutical industry. This implies that a truly 
effective and appropriate supply chain management performance method is one that uses 
a flexible or dynamic set of variables (or dimensions) instead of a rigid one (Ahmad, 
Usman, Raouf, & Sparks, 2009). This, in theory, should enable the person, group, or 
organization conducting the supply chain performance evaluation process to test a certain 
industry’s supply chain framework’s performance based on the variables or dimensions 
that truly matter because it is the appropriate step to take and not just because it had been 
included in some standardized evaluation method or questionnaire (Shah, 2004). Above 
mentioned argument or finding coincides with what other previously published literature 
about the creation of a unified way to evaluate supply chain management performance in 
relation to the pharmaceutical industry. 
Drug Discovery 
Drug discovery refers to the process by which drugs that have the potential to cure 
a still incurable disease or to cure an already curable one, but in a more effective and or 
efficient manner, get designed or discovered (Dunlap, Kotabe, & Mudambi, 2010). 
Traditionally, drug discovery processes have worked by merely enabling the scientists to 
isolate the active components of an ingredient or any drug raw materials and use it to 
scale up or intensify the effects of certain traditional remedies. This traditional model of 
drug discovery has worked for many years. It has also enabled the still growing 
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pharmaceutical industry to establish a strong understanding of how drug ingredients and 
raw materials and their active components can be studied, isolated, and crafted for safe 
and effective human consumption (Guler & Nerkar, 2012). This paved the way for a 
more modern and theoretically more efficient and effective way of discovering new 
drugs. Instead of just focusing on the progress made by the material understanding of 
drugs, modern pharmaceutical and biotechnology firms use their updated understanding 
of how the body works. At this point, there is also the accumulation of concepts that are 
derived from other fields (Kolb & Sharpless, 2003). There are, for example, components 
of biotechnology, anatomy, physiology, and pharmacology, and pharmacokinetics. One 
strategy that modern drug discovery and development firms use is that they focus on 
using their understanding of the different metabolic pathways of the body and how they 
work in relation to the drugs and the collection of active ingredients that they introduce. 
This way, they can study and therefore module the target patients’ responses from both 
sides, both from the side where they revise the components of the drug that is being 
conceptualized, and the side where they revise the effects of the drug’s plasticity in as far 
as the nature and the structure of the target metabolic pathways are concerned (Wilson, 
Williams, Jones, & Andrews, 2012). This more contemporary process of drug discovery 
essentially allows pharmaceutical firms to develop more efficient products, ones that are 
slightly less potent but can still create the same effects as their more powerful 
counterparts. This is made possible by the process that lets them target certain metabolic 
pathways and take advantage of other naturally occurring metabolic mechanisms to 
deliver the drug payload faster and achieve higher absorption and bioavailability rates, 
among other metrics and metric-related improvements (Schouten et al., 2011).  
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Despite the already significant impact of this contemporary method of discovering 
new drugs that can be introduced into a variety of markets, new and more updated 
methods of drug discovery are still being developed. One of the most prominent of which 
is click chemistry. In a study that was featured in Drug Discovery Today, a group of 
researchers examined how click chemistry is changing the drug discovery landscape 
(Kolb & Sharpless, 2003). In the said study, they defined the parameters that can be used 
to correctly identify when a pharmaceutical firm or any pharmaceutical industry 
participant is using click chemistry to reach its organizational goals and objectives. Kolb 
& Sharpless (2003) define click chemistry as a modular approach that makes use of the 
most practical, efficient, and reliable means of chemical transformation. The importance 
of optimizing these functions cannot be understated because they serve as the backbone 
of the modern drug discovery process. Its applications can be found in all aspects of drug 
discovery such as lead generation using combinatorial chemistry and template-based and 
targeted in situ chemistry, DNA research, proteomics, and the study and use of bio-
conjugation reactions (Kolb & Sharpless, 2003). It is important to note that a typical drug 
lead discovery process is laborious in that it takes a lot of time, effort, and resources from 
the company that is spearheading the operations. With click chemistry, the goal is not to 
completely replace the other existing drug discovery methods but to simply complement 
and extend their reaches. In the case of the Copper-I-catalyzed 1, 2, 3-Triazole formation 
from terminal acetylenes and azides that was the subject of Kolb & Sharpless’ (2003) 
study, for example, their goal of using click chemistry was to simply optimize the process 
by understanding more about the associations between the chemically transformed 
compounds and ingredients and their biological targets, i.e. how the specific body 
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systems, organs, and or cells would react when the said agents get introduced (Wilson, 
Williams, Jones, & Andrews, 2012). 
Despite the already numerous developments in the process of drug discovery and 
the finite number of compounds that can be used for eventual drug development 
programs, the pharmaceutical firms’ ability to discover new drugs is still fairly limited. 
One of the hindrances that was identified in previously published studies is the slow and 
complex synthesis technique used to discover and develop natural products, or what is 
also referred to in the pharmaceutical industry as compound synthesis (Guler & Nerkar, 
2012). Click chemistry relies on the use of a highly selective, discriminative, and as a 
result, near-perfect method of synthesizing compounds. Some of the common 
requirements in a click chemistry- based drug discovery process include the use of a wide 
scope (so that a larger pool of drug-related compounds can be discovered and 
regenerated, i.e. higher yields for and varieties of starting materials), and the selection of 
processes that are easy to perform, insensitive to water and oxygen, and only makes use 
of readily available reagents, and whose reaction work-up and product isolation processes 
do not require chromatographic purification (Kolb & Sharpless, 2003). Without going 
much into the technical details, the emergence of click chemistry serves as concrete 
evidence that the drug discovery landscape in the pharmaceutical industry is still being 
continuously developed and this can be considered a positive type of development. This 
means that there will be potentially more marketable pharmaceutical products in the 
future and more patients will be able to benefit from such products and the relief (from 
medical and physical conditions) that they offer (Guler & Nerkar, 2012). Focusing on the 
supply chain management performance side, however, this will also mean greater 
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constraints and a higher demand for more optimized supply chain management practices. 
As the pharmaceutical grows in size and complexity, so should its underlying supply 
chain management framework. Otherwise, the supply chain performance can be a 
potential issue, a bottleneck even, that may hamper the otherwise healthy growth and 
expansion of the pharmaceutical industry (Schouten et al., 2011). 
Drug Development 
Drug development is another major procedural component being undertaken by 
pharmaceutical firms. This procedure often succeeds the completion of the drug 
discovery process. When a drug has been successfully discovered, the newly discovered 
compound would already be considered as a potentially marketable product (Dunlap, 
Kotabe, & Mudambi, 2010). However, it would still be subject to various processes 
before the newly discovered compound would be allowed to be sold to prospective 
consumers. This is where the numerous subcomponents of the drug development phase 
would come in. The drug development phase refers to the collection of processes done to 
more formally establish the suitability of the newly discovered compound as a medication 
(Wilson, Williams, Jones, & Andrews, 2012). Some of the key objectives of a 
pharmaceutical firm that is conducting drug development operations include the 
determination of appropriate formulation, dosing, list of indications, contraindications, 
and precautions, and establishing supply chain related components such as what types of 
synthetic and natural raw materials to use and where to source them from (Wilson, 
Williams, Jones, & Andrews, 2012). This is the area in which a pharmaceutical firm who 
wants to introduce a new brand or product to the market files a new drug or 
pharmaceutical product application before a certain country’s drug regulatory agency and 
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begins to conduct a complex combination of in vitro studies, in vivo studies, and large 
scale clinical trials (Guler & Nerkar, 2012). Each of these drug development components 
is divided into various sub-components. The clinical phase, which is arguably the most 
important, for example, can be divided into four sub-phases, namely Phase I, II, III, and 
IV. Across all phases, the targets are not animals anymore but actual human subjects 
(Wilson, Williams, Jones, & Andrews, 2012). Under Phase I, healthy human volunteers 
are the ones that get recruited; the main goal of which is to establish a safety and dosing 
protocol for the drug that will be marketed. Phase II clinical trials are a little bit different 
in that they are used to conduct an initial evaluation of the efficacy of the product being 
tested, focusing on a small population of non-healthy patients, particularly those who 
have the disease that is being targeted (Dunlap, Kotabe, & Mudambi, 2010). Phase III 
clinical trials are essentially the same as Phase II; the only difference is that the 
population size of the patients who have the disease that is being targeted would normally 
be significantly larger. Phase IV clinical trials are the least intensive but most extensive, 
at least in theory. This is because the fourth phase is where market surveillance studies 
and other post-approval trials based on the drug regulatory agency’s requirements will 
normally be conducted. It is important to note that the progression of the clinical trial 
phases is sequential and not simultaneous; that is, the drug development process cannot 
proceed to the next stage or phase without completing the first one (Schouten et al., 
2011). 
There have also been numerous developments in the drug development side of the 
pharmaceutical industry that are aimed at modernizing and optimizing the way by which 
new drugs and other pharmaceutical products get developed. In the drug development-
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related operational advancements with supply chain management and performance-
related implications, one development that is worth discussing is vertical product (i.e. 
drug) development integration (Dunlap, Kotabe, & Mudambi, 2010). 
Pakistan’s Pharmaceutical Industry in relation to the Global Pharmaceutical 
Industry   
The pharmaceutical firms that are operating in the country are not full-blown ones 
like Abbott, Merck, and GlaxoSmithKline. The majority of the pharmaceutical industry 
firms that are doing business in the country are merely operating units (Khan, 2012). 
Operating units can either be a partially or wholly owned overseas subsidiary of a 
multinational corporation, i.e. a pharmaceutical industry giant, or a locally owned 
business venture that supplies active drug ingredients and other precursors to the 
companies that are in charge of manufacturing and distributing the final output to the 
consumers; these are the drugs and the pharmaceutical products that have been 
manufactured using the active drug ingredients and precursors supplied by the 
pharmaceutical firms in Pakistan (Zaman, 2011). This means that on a global scale, 
Pakistan’s pharmaceutical industry serves as the producer of raw materials that the actual 
drug manufacturers, companies located overseas, use to produce their final outputs. It is a 
problem because in a typical supply chain environment, the further up one goes in the 
hierarchy of producers, the thinner the profit margin becomes. This is why the companies 
and countries that are in charge of supplying raw materials needed for the drug 
manufacturers to produce drugs and other pharma products are the ones that have the 
lowest earnings (Khan, 2012). The drug manufacturers, whose main role is to assemble 
the raw materials (i.e. active drug ingredients and precursors, among other components 
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that are essential to the manufacturing process) coming from the operating units in 
countries like Pakistan, on the other hand, earn the highest. Although the difference is 
normal, it is considered a problem because this can be interpreted as an indicator that the 
government as represented by the policymakers and the members of the private sector are 
not doing enough to ensure and secure the long-term growth and sustainability of the 
pharmaceutical industry and its underlying supply chain network (Ramanathan, 2009). 
For Pakistan’s pharmaceutical industry’s supply chain network to truly grow, it needs to 
go down the ladder and evolve from being just a raw material, active drug ingredients, 
and drug precursor’s supplier to being a full-blown drug manufacturer. The problem with 
this goal is that there are many malpractices within Pakistan’s pharmaceutical industry’s 
supply chain that lead to inefficiencies and low quality of output. These ultimately create 













 The goal of this study was to examine the supply chain management performance 
of the pharmaceutical industry in Pakistan as perceived by industry professionals in 
Pakistan. Data was collected through questionnaires that would facilitate quick analysis 
and interpretation of information gathered. The questions were administered to a selected 
sample of the participants that represent every sector of the industry including the 
multinationals, local manufacturers, retailers, and regulators. The results of the study 
suggested that the manufacturers are not managing lead-time properly due to factors such 
as government regulations, manufacturers lack consistency in terms of Supply Chain 
Flexibility/Agility Performance, Supply Chain Resource Performance, and Supply Chain 
Output Performance. These were the three metrics that were used to describe the 
independent variable which is the supply chain performance of Pakistan’s pharmaceutical 
industry. 
Participants and Data Sets 
The study focused on the main participants in the pharmaceutical manufacturing 
sectors in the country. As such, the respondents were composed of managers, marketers, 
pharmaceutical retail outlets, and independent distributors. Through the questionnaires, 
the respondents provided information that measures various aspects of SCM. The sample 
size was 60. This included managers of pharmaceutical firms and companies, including 
but not limited to manufacturers, wholesalers, and retailers, and basically any company 




The manufacturers, wholesalers, and retailers, and basically any company that can 
be identified as a stakeholder in Pakistan’s pharmaceutical industry’s supply chain 
framework were selected as the sample population because their opinions and perceptions 
could be used as not only an adequate but also a reliable representation of the opinions 
and perceptions of the entire Pakistani pharmaceutical industry’s supply chain. Upon 
closer analysis, one would find that these individuals belong to the Pakistani 
pharmaceutical industry’s supply chain network. The manufacturers are those producing 
the product; the wholesalers and retailers act as their distributors. The key requirement 
here was that they should be fundamentally identified as a stakeholder, meaning they had 
vested interests in the pharmaceutical industry of Pakistan’s supply chain framework. 
In order to meet the target sample population size of 60 Pakistani pharmaceutical 
firm employees, a combination of various sampling techniques and procedures was used 
by the research team. There was a total of two independent sampling techniques, 
convenience sampling and snowball sampling, both of which are non-probability types of 
sampling. Convenience sampling is where the research team recruit and shortlist 
respondents based on the two parties’ availability (that of the researchers and the target 
respondents) (Zaman, 2011). The rationale behind the use of convenience sampling was 
to be able to save time and maximize the efficiency of the research’s implementation 
phase. The convenience sampling technique was used to recruit the first few respondents. 
After recruiting the first few respondents, the snowball sampling technique was used. 
This is where the already recruited respondents recruit their friends, colleagues, and 
acquaintances who are working in the same field. They will be referred to the researchers 
so that they may also be included in the list of prospective respondents, hence the term 
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snowballing (Ramanathan, 2009). The rationale behind the use of this sampling technique 
was convenience and efficiency. It is important to note, however, that a set of inclusion 
criteria was still used to screen the respondents. The goal of which was to make sure that 
all of the 60 respondents were an appropriate representative of the target population 
whose perceptions about the supply chain performance of Pakistan’s pharmaceutical 
industry was examined. The most important qualification was that the respondents should 
be an employee of a pharmaceutical firm that is based in Pakistan; a respondent should 
have at least a 4 year working experience in the field and at least a 2 year tenure working 
as an employee of his or her current company. Respondents with less than 1 year 
experience would be included based on the level of education completed. In order to 
minimize the effects of other non-Supply Chain Management related variables on the 
outcome of the data analysis, there was an equal division of the total sample population in 
terms of gender. Information was not collected in terms of culture, social class and status, 
and the hierarchy of company position. 
Data Collection, Instruments, and Procedures 
A custom questionnaire featured in a Malaysian doctoral dissertation that was also 
aimed at examining the performance of an industry’s underlying supply chain 
management practices was used as the main research instrument in this study. It used a 7 
Point Likert Scale type of question. It measured the target industry’s Supply Chain 
Performance based on numerous dimensions, namely Supply Chain Management 
Practices, Supply Chain Integration, the actual Supply Chain Performance, and 
Demographic Profiles (Pandiyan, n.d.). Because this paper only focused on SCM 
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performance, the third dimension that was featured in the said questionnaire, which is on 
the actual Supply Chain Performance was the focus. 
Method of Data Analysis 
The online survey gathering primary information used the questionnaire which 
was sent through email via contacting the participant through email or telephone in the 
field that was referenced earlier. The goal of which was to examine how the respondents 
rate the supply chain performance of Pakistan’s pharmaceutical industry using a 7 point 
Likert Scale. Using the assumption that was presented earlier, the respondent’s 
perceptions were an accurate predictor of the actual performance of Pakistan’s 
pharmaceutical industry’s supply chain framework.  
The data analysis phase succeeded the data gathering and other phases included in 
the implementation proper of the study. The data analysis focused on the use of 
descriptive statistics. Descriptive statistics were used to present a summary of what the 
respondents suggested in relation to the performance of Pakistan’s pharmaceutical 
industry’s supply chain. Since a 7 Point Likert Scale was used, a quantitative 
representation of the data was used. Based on how the questionnaire was presented, the 
mean or average score for each questionnaire item, questionnaire dimension, and 
eventually the entire questionnaire was obtained. The closer to 7 (which is the maximum 
positive score) the average score was, the more positive it was. The lowest possible score 
was 1; a score of 1, in this case, meant that the average perception of the respondents 




Results and Findings 
 The results and findings of the study were summarized using the set of tables below. 
The case processing summary table below shows that there was a perfect response rate in 
all questionnaire items. This can be evidenced by the N, total number of responses, in the 
table’s second column.  
Table 1  





Included Excluded Total 
N Percent N Percent N Percent 
D1 60 100.0% 0 0.0% 60 100.0% 
D2 60 100.0% 0 0.0% 60 100.0% 
D3 60 100.0% 0 0.0% 60 100.0% 
D4 60 100.0% 0 0.0% 60 100.0% 
SC1 60 100.0% 0 0.0% 60 100.0% 
SC2 60 100.0% 0 0.0% 60 100.0% 
SC3 60 100.0% 0 0.0% 60 100.0% 
SC4 60 100.0% 0 0.0% 60 100.0% 
SC5 60 100.0% 0 0.0% 60 100.0% 
RP1 60 100.0% 0 0.0% 60 100.0% 
RP2 60 100.0% 0 0.0% 60 100.0% 
RP3 60 100.0% 0 0.0% 60 100.0% 
RP4 60 100.0% 0 0.0% 60 100.0% 
RP5 60 100.0% 0 0.0% 60 100.0% 
OP1 60 100.0% 0 0.0% 60 100.0% 
OP2 60 100.0% 0 0.0% 60 100.0% 
OP3 60 100.0% 0 0.0% 60 100.0% 
OP4 60 100.0% 0 0.0% 60 100.0% 
OP5 60 100.0% 0 0.0% 60 100.0% 
OP6 60 100.0% 0 0.0% 60 100.0% 
OP7 60 100.0% 0 0.0% 60 100.0% 
Note. Limited to first 60 cases. 
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Table 2  
Demographics 





Included Excluded Total 
N Percent N Percent N Percent 
D1 60 100.0% 0 0.0% 60 100.0% 
D2 60 100.0% 0 0.0% 60 100.0% 
D3 60 100.0% 0 0.0% 60 100.0% 
D4 60 100.0% 0 0.0% 60 100.0% 
Note. Limited to first 60 cases. 
 
The case summary for the Demographic Profile of the respondents shows that in 
terms of the size of the organization, pharmaceutical firms composed of less than 50 and 
more than 500 employees were the most represented; each had a 23% allocation. In terms 
of revenues, the Pakistani pharmaceutical firms with revenues between 1 to 5 Million 
were the most frequently surveyed; they represented 23% of the respondent population. 
This was closely followed by Pakistani pharmaceutical firms with revenues between 50 
to 100 Million; they represented 21.7% of the respondent population. In terms of the 
respondents’ total years of experience working for their current company, those with 
between 5 to 10 years of experience were the largest part of the population at 21.7%. In 
terms of their highest educational attainment, those with only a Technical / Vocational 







Table 3  




D1 D2 D3 D4 
 
1 More than 500 50 to 100 
Million 
1 to 5 years Technical or Vocational 
Education 
 
2 100 to 250 1 to 5 Million  5 to 10 Years Technical or Vocational 
Education  
 
3 More than 500 5 to 10 
Million  
10 to 15 Years  Secondary School  
4 50 to 100 More than 
100 Million 
10 to 15 Years Ph.D./Doctorate Degree  
5 More than 500 1 to 5 Million 15 to 20 Years Intermediate Higher 
Secondary School 
 
6 250 to 500 Less than 1 
Million 
More than 20 
Years 
Ph.D./Doctorate Degree  
7 More than 500 10 to 50 
Million 
15 to 20 Years Ph.D./Doctorate Degree  
8 100 to 250 Less than 1 
Million 





9 More than 500 More than 
100 Million 
5 to 10 Years Technical or Vocational 
Education 
 
10 50 to 100 5 to 10 
Million 
10 to 15 Years Ph.D./Doctorate Degree  
11 250 to 500 50 to 100 
Million 
10 to 15 Years Secondary School  
12 50 to 100 50 to 100 
Million 
15 to 20 Years Intermediate Higher 
Secondary School 
 
13 Less Than 50 Less than 1 
Million 





14 50 to 100 5 to 10 
Million 
More than 20 
Years 
Ph.D./Doctorate Degree  
15 Less Than 50 1 to 5 Million 5 to 10 Years Technical or Vocational 
Education 
 







D1 D2 D3 D4 
 
17 50 to 100 50 to 100 
Million 
5 to 10 Years Intermediate Higher 
Secondary School 
 
18 100 to 250 5 to 10 
Million 
5 to 10 Years Technical or Vocational 
Education 
 
19 Less Than 50 More than 
100 Million 
10 to 15 Years Intermediate Higher 
Secondary School 
 
20 100 to 250 10 to 50 
Million 
1 to 5 Years Intermediate Higher 
Secondary School 
 
21 250 to 500 5 to 10 
Million 
15 to 20 Years Master's Degree  
22 100 to 250 More than 
100 Million 
10 to 15 Years Bachelor's Degree  
23 More than 500 10 to 50 
Million 
15 to 20 Years Technical or Vocational 
Education 
 
24 More than 500 More than 
100 Million 
5 to 10 Years Secondary School  
25 250 to 500 1 to 5 Million 10 to 15 Years Master's Degree  
26 50 to 100 10 to 50 
Million 
More than 20 
Years 
Secondary School  
27 100 to 250 1 to 5 Million 15 to 20 Years Technical or Vocational 
Education 
 
28 Less Than 50 1 to 5 Million Less than 1 
Year 
Ph.D./Doctorate Degree  
29 Less Than 50 Less than 1 
Million 
5 to 10 Years Technical or Vocational 
Education 
 
30 100 to 250 50 to 100 
Million 
Less than 1 
Year 
Ph.D./Doctorate Degree  
31 Less Than 50 1 to 5 Million 5 to 10 Years Ph.D./Doctorate Degree  
32 100 to 250 More than 
100 Million 
1 to 5 Years Bachelor's Degree  
33 250 to 500 1 to 5 Million Less than 1 
Year 
Bachelor's Degree  
34 More than 500 10 to 50 
Million 







D1 D2 D3 D4 
 
35 More than 500 Less than 1 
Million 
10 to 15 Years Technical or Vocational 
Education 
 
36 250 to 500 More than 
100 Million 
15 to 20 Years Master's Degree  
37 250 to 500 Less than 1 
Million 
15 to 20 Years Bachelor's Degree  
38 More than 500 5 to 10 
Million 
1 to 5 Years Technical or Vocational 
Education 
 
39 Less Than 50 10 to 50 
Million 
5 to 10 Years Technical or Vocational 
Education 
 
40 250 to 500 50 to 100 
Million 
1 to 5 Years Master's Degree  
41 50 to 100 More than 
100 Million 





42 Less Than 50 50 to 100 
Million 
Less than 1 
Year 
Secondary School  
43 Less Than 50 Less than 1 
Million 
5 to 10 Years Master's Degree  
44 100 to 250 Less than 1 
Million 
5 to 10 Years Secondary School  
45 250 to 500 50 to 100 
Million 
5 to 10 Years Master's Degree  
46 100 to 250 10 to 50 
Million 





47 50 to 100 1 to 5 Million Less than 1 
Year 
Technical or Vocational 
Education 
 
48 Less Than 50 1 to 5 Million More than 20 
Years 
Ph.D./Doctorate Degree  
49 100 to 250 1 to 5 Million Less than 1 
Year 
Secondary School  
50 100 to 250 50 to 100 
Million 
Less than 1 
Year 
Secondary School  
51 Less Than 50 5 to 10 
Million 
5 to 10 Years Master's Degree  
52 250 to 500 50 to 100 
Million 







D1 D2 D3 D4 
 
53 Less Than 50 50 to 100 
Million 
1 to 5 Years Master's Degree  
54 More than 500 More than 
100 Million 
10 to 15 Years Master's Degree  
55 250 to 500 5 to 10 
Million 





56 250 to 500 1 to 5 Million 15 to 20 Years Bachelor's Degree  
57 Less Than 50 50 to 100 
Million 
More than 20 
Years 
Technical or Vocational 
Education 
 
58 More than 500 Less than 1 
Million 
10 to 15 Years Ph.D./Doctorate Degree  
59 More than 500 1 to 5 Million 15 to 20 Years Secondary School  
60 More than 500 50 to 100 
Million 
Less than 1 
Year 























Less Than 50 
 


























Less than 1 
Year 
 



























Table 4  
Supply Chain Flexibility Performance 





Included Excluded Total 
N Percent N Percent N Percent 
SC1 60 100.0% 0 0.0% 60 100.0% 
SC2 60 100.0% 0 0.0% 60 100.0% 
SC3 60 100.0% 0 0.0% 60 100.0% 
SC4 60 100.0% 0 0.0% 60 100.0% 
SC5 60 100.0% 0 0.0% 60 100.0% 
Note. Limited to first 60 cases. 
 
This discussion about the supply chain flexibility or agility performance-related 
findings focused on the overall score for each subgroup. Because a 7 Point Likert Scale 
was used, the performance for each cluster can be measured using any number between 1 
and 7, with 1 being the lowest possible score and 7 being the highest. For the entire 
supply chain flexibility or agility performance group of questions, the overall score was 
4.18. This represents a neutral score, neither positive nor negative. The computed means 












Table 5  
Supply Chain Flexibility Case Summaries 
Case Summaries 















Neutral Neutral Excellent Very 
Satisfactory 










6 Neutral Satisfactory Negative Very 
Satisfactory 
Satisfactory 
7 Negative Satisfactory Neutral Satisfactory Satisfactory 





Negative Satisfactory Neutral Excellent 
10 Very 
Satisfactory 









12 Negative Excellent Negative Excellent Neutral 
13 Very 
Negative 
Negative Excellent Satisfactory Satisfactory 































































































Excellent Satisfactory Excellent 
29 Very 
Satisfactory 
Satisfactory Neutral Very 
Satisfactory 
Negative 
30 Excellent Very 
Satisfactory 
Excellent Negative Very 
Satisfactory 









33 Negative Excellent Slightly 
Negative 
Satisfactory Satisfactory 










Case N SC1 SC2 SC3 SC4 SC5 





36 Negative Very 
Satisfactory 
Excellent Excellent Excellent 
37 Very 
Satisfactory 
Satisfactory Neutral Neutral Excellent 




















Neutral Negative Excellent 
41 Excellent Slightly 
Negative 
Neutral Excellent Negative 





43 Negative Very 
Negative 
Satisfactory Excellent Neutral 






45 Negative Neutral Negative Neutral Excellent 










48 Satisfactory Excellent Excellent Satisfactory Very 
Satisfactory 
49 Negative Negative Slightly 
Negative 
Neutral Satisfactory 















Case N SC1 SC2 SC3 SC4 SC5 
53 Negative Neutral Excellent Excellent Negative 














57 Satisfactory Satisfactory Slightly 
Negative 
Excellent Satisfactory 
58 Negative Slightly 
Negative 









































































Table 6  
Resource Performance 





Included Excluded Total 
N Percent N Percent N Percent 
RP1 60 100.0% 0 0.0% 60 100.0% 
RP2 60 100.0% 0 0.0% 60 100.0% 
RP3 60 100.0% 0 0.0% 60 100.0% 
RP4 60 100.0% 0 0.0% 60 100.0% 
RP5 60 100.0% 0 0.0% 60 100.0% 
Note. Limited to first 60 cases. 
 
The Resource Performance Cluster was represented by items RP1 to RP5. RP1’s 
average was 3.86; RP2 was at 4.33; RP3 at 3.95; RP4 at 3.66 and RP5 came in at 3.53. 
The mean for the entire Resource Performance Cluster was 3.87, out of a maximum score 
of 7. This means that from a statistical perspective, the Resource Performance of the 
Pakistani pharmaceutical industry’s supply chain was more negative than positive. This 
can be evidenced by the fact that the overall score for this cluster went below the neutral 












Table 7  
Resource Performance Case Summaries 
Case Summaries 








































































































Case N RP1 RP2 RP3 RP4 RP5 
17 























































































Excellent Satisfactory Negative Neutral Satisfactory 
32 Slightly 
Negative 
































































































































Negative Satisfactory Negative 
50 Very 
Satisfactory 

























Satisfactory Satisfactory Excellent 
54 










































































































Table 8  
Output Performance 





Included Excluded Total 
N Percent N Percent N Percent 
OP1 60 100.0% 0 0.0% 60 100.0% 
OP2 60 100.0% 0 0.0% 60 100.0% 
OP3 60 100.0% 0 0.0% 60 100.0% 
OP4 60 100.0% 0 0.0% 60 100.0% 
OP5 60 100.0% 0 0.0% 60 100.0% 
OP6 60 100.0% 0 0.0% 60 100.0% 
OP7 60 100.0% 0 0.0% 60 100.0% 
Note. Limited to first 60 cases. 
 
The Output Performance questionnaire item cluster was represented by OP1 to 
OP7. The average for each can be found in the descriptive statistics table at the end of 
results and findings. The mean for the entire Output Performance Cluster was 4.05. This 
put it closer to the score obtained in the Supply Chain Agility Performance Cluster. This 
means that it too has a more natively neutral score as evidenced by its statistical closeness 
to the score of 4.0.
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Table 9  
Output Performance Case Summaries 
Case Summaries  
Case 
N 










2 Neutral Satisfactory Negative Satisfactory Satisfactory Neutral Excellent 
3 Neutral Excellent Neutral Excellent Negative Satisfactory Very 
Satisfactory 









Satisfactory Satisfactory Slightly 
Negative 
Neutral 








Excellent Satisfactory Slightly 
Negative 
Satisfactory Negative 

























OP1 OP2 OP3 OP4 OP5 OP6 OP7 




Negative Satisfactory Slightly 
Negative 
Satisfactory 




Satisfactory Excellent Neutral Excellent 































Satisfactory Excellent Satisfactory 






















Neutral Negative Negative 
20 Negative Negative Very 
Negative 




Neutral Excellent Very 
Satisfactory 
Neutral Neutral Satisfactory 
22 Very 
Negative 








OP1 OP2 OP3 OP4 OP5 OP6 OP7 






























Satisfactory Satisfactory Neutral Neutral 
27 Very 
Satisfactory 











































































































































































































Satisfactory Neutral Satisfactory 
49 Slightly 
Negative 



















































Excellent Negative Excellent 
55 Slightly 
Negative 
















































































































Note. Limited to first 60 cases.
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Based on the Results and Findings from the 3 clusters, it can be seen that the 
Supply Chain Agility Performance and Output Performance were virtually tied. The main 
weakness of the Supply Chain Network of Pakistan’s Pharmaceutical Industry was its 
Resource Performance. This was evidenced by the fact that it got the lowest score, below 
the neutral score of 4.0. 
Table 10  




N MIN MAX Mean  STDEV  
D1 60 1 5 3.07 1.494  
D2 60 1 6 3.47 1.732  
D3 60 1 6 3.48 1.631  
D4 60 1 6 3.53 1.722  
SC1 60 1.00 7.00 4.2167 2.18695  
SC2 60 1.00 7.00 4.0333 1.95688  
SC3 60 1.00 7.00 4.2667 1.96466  
SC4 60 1.00 7.00 4.0667 2.12225  
SC5 60 1.00 7.00 4.3500 2.09782  
RP1 60 1.00 7.00 3.8667 2.08682  
RP2 60 1.00 7.00 4.3333 1.98013  
RP3 60 1.00 7.00 3.9500 1.89938  
RP4 60 1.00 7.00 3.6667 1.98867  
RP5 60 1.00 7.00 3.5333 2.07051  
OP1 60 1.00 7.00 4.0500 1.90828  
OP2 60 1.00 7.00 3.9833 1.89103  
OP3 60 1.00 7.00 4.1833 2.19005  
OP4 60 1.00 7.00 4.3333 1.93686  
OP5 60 1.00 7.00 3.9667 1.98269  
OP6 60 1.00 7.00 3.8667 1.83623  
OP7 60 1.00 7.00 3.9833 2.00416  
Valid N 
(listwise) 
60      
Note. Limited to first 60 cases. 
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The main findings that were important for the research’s objectives were 
mentioned in the discussions of the findings per cluster. A more important part to 
mention would be the descriptive statistics table. This was the reference table used to 
compute the average score per cluster. The grand mean for the entire questionnaire from 
SC1 to OP7 was 4.03. This means that overall, the performance of Pakistan’s 
Pharmaceutical Industry’s Supply Chain was neither negative nor positive, only neutral. 
For further analysis of per question cluster summary and percentage response, consult 





















Conclusions and Recommendations 
 The objective of this study was to examine the supply chain network performance 
of the pharmaceutical industry in Pakistan. A quantitative research design was used in the 
present study to meet the research aims and objectives. A custom- made questionnaire was 
used in order to collect data from the respondents. There was a total of 60 respondents, all 
of whom were members of Pakistan’s pharmaceutical industry’s supply chain network. It 
has been asserted that the pharmaceutical industry’s SCM practices play an integral role in 
the maintenance of a fully functional pharmaceutical industry. This was an important 
investigation of Pakistan’s pharmaceutical industry’s supply chain performance. This was 
evaluated using the custom-made questionnaire. The 60 respondents were chosen based on 
the assumption that they are the ones with the most reliable and sufficient knowledge of 
the target industry. A thorough review of the related literature was also conducted in an 
effort to back up the claims, assumptions, and expectations that were made with data 
coming from previously published studies. The consensus was that the pharmaceutical 
industry in Pakistan’s supply chain framework has been underperforming for many years 
already. This consensus was backed by numerous previously published studies. It is worth 
noting, however, that the industry and its supply chain network is still growing at a very 
fast rate. At its current state, there have been numerous areas of improvement that were 
noted. In order to conduct a more precise analysis of Pakistan’s pharmaceutical industry’s 
supply chain network, the questionnaire was divided into three clusters. It is worth noting 
that supply chain flexibility/agility, resource performance, and output performance were 
the top three variables that were covered in this study. Each of the variables was divided 
into different questions. Supply chain flexibility performance and resource performance 
were divided into five individual questionnaire items. The data analysis focused on 
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providing a summary of the cases that were analyzed, all 60 of them, across all of the 
questionnaire items and clusters. Data that showed the descriptive statistical analysis 
outcomes were also shown.  
 In order to analyze the data, one has to know how the questionnaire items were 
graded. A 7 Point Likert Scale was used to answer all of the questions, except for D1 
(Demographic) to D4. Based on how the questionnaire was created, a score that is closer 
to 7 would indicate a positive perception about a specific cluster or cluster item. The 
opposite of this would be true for a score that is closer to 1. In general, the higher the score 
is, the more positive the performance of the Pakistani pharmaceutical industry’s supply 
chain network. Focusing on the results, the mean for the supply chain agility or flexibility 
performance was 4.21. The mean for the resource performance cluster was 3.86. The mean 
for output performance was 4.05. A score of 4 represents neutrality (neither positive nor 
negative). Individually, the per-cluster mean scores show an affinity towards neutrality. 
The grand mean score across all of the 3 clusters was 4.04. This means that the perceptions 
of the respondents, all of whom were verified members of Pakistan’s pharmaceutical 
industry’s supply chain network, suggest that performance was neither positive nor 
negative. This leads to the question on whether this key finding is in line with the 
expectations and research questions, and the outcomes of the review of related literature. 
The answer is yes. It is worth mentioning that the consensus was that Pakistan’s 
pharmaceutical industry’s SCM performance still has a lot of room for improvement but 
that it is also improving and growing at an impressively fast rate. An overall score of 4.04 
was in line with this consensus. It would, therefore, be safe to suggest that the results and 
findings of this study validate that of the previously published studies. 
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 One of the limitations of this study was that only a small sample size was used, i.e. 
60 respondents. The recommendation for future researchers then would be to make use of 
a significantly larger sample population. Another recommendation would be to focus more 
on one supply chain management aspect, one of the three clusters so that a narrower 
research question and a corresponding set of objectives could be developed. For the 
stakeholders of the study, the recommendation is to make use of the results and findings 
found in this study to focus on the aspects that were listed under the three clusters: supply 
chain flexibility, resource performance, and output performance. The weakest area was 
identified to be the resource performance area of Pakistan’s pharmaceutical industry’s 
supply chain network as it got the lowest score of 3.86, significantly below the 4 which 
was the neutral territory. This may be because the total resources used, cost of distribution 
(including transportation and handling costs), cost of manufacturing, labor, maintenance, 
and re-work, inventory, and low returns on investment were found to be less than optimal 
in this cluster. It is worth noting, however, that this score is not far away from the scores 












Appendix A: Questionnaire and Per Question Cluster Summary  
 
 
Supply Chain Performance in the Pharmaceutical Industry in Pakistan Questionnaire  
Instruction: Rate each aspect of Pakistan's 
Pharmaceutical Industry's Supply Chain 
Performance by choosing/putting a mark on the 
best description that applies 
Very 
Negative      
(1) 





Neutral            
(4) 
Satisfactory                     
(5) 
Very 
Satisfactory            
(6) 
Excellent               
(7) 
Supply Chain Flexibility/Agility Performance 
(FP)               
Ability to respond to and accommodate demand 
variations, such as seasonality.               
Ability to respond to and accommodate the periods 
of poor manufacturing performance such as machine 
breakdown.               
Ability to respond to and accommodate the periods 
of poor supplier performance.               
Ability to respond to and accommodate the periods 
of poor delivery performance.                
Ability to respond to and accommodate new 
products, new markets, or new competitors.               
Supply Chain Resource Performance (RP) 
              
Total cost of resources used 
              
Total cost of distribution, including transportation 
and handling cost               
Total cost of manufacturing, including labor, 
maintenance, and re-work cost.               
Cost associated with held inventory 
              
Return on investment 
              
Supply Chain Output Performance (OP) 
              
Sales 
              
Order Fill Rate 
              
On-Time Deliveries 
              
Customer Response Time 
              
Shipping Errors 
              
Manufacturing Lead Time 
              
Customer Complaints 
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Demographic profile of company 
Please check (√) the appropriate box/column  
D1. Numbers of Employees at 
company: 
  Less than 50 
  50 - 100 
  100 - 250 
  250 - 500 
  More than 500 
D2. Annual sales of this company in 
(RS) is:                                                        
  Less than 1 million 
  1 – 5 million 
  5 – 10 million 
  10 – 50 million 
  50 – 100 million 
  More than 100 million 
D3. Years of experience at this 
company: 
  Less than 1 year 
  1 – 5 years 
  5 – 10 years 
  10 – 15 years 
  15 – 20 years 
  More than 20 years 
D4. What is your highest level of 
education completed  
 Matriculation-Secondary 





 Bachelor’s degree 
 Master’s degree  
 Ph.D./Doctorate degree  





Per Question Cluster Summaries 
D1 
 Value Count Percent 
Standard Attributes Position 1   
Label <none>   
Type Numeric   
Format F8   
Measurement Nominal   
Role Input   
Valid Values 1 Less Than %0 14 23.3% 
2 50 to 100 8 13.3% 
3 100 to 250 12 20.0% 
4 250 to 500 12 20.0% 
5 More than 500 14 23.3% 
 
D2 
 Value Count Percent 
Standard Attributes Position 2   
Label <none>   
Type Numeric   
Format F8   
Measurement Nominal   
Role Input   
Valid Values 1 Less than 1 
Million 
9 15.0% 
2 1 to 5 Million 14 23.3% 
3 5 to 10 Million 8 13.3% 
4 10 to 50 Million 7 11.7% 
5 50 to 100 Million 13 21.7% 











 Value Count Percent 
Standard Attributes Position 4   
Label <none>   
Type Numeric   
Format F8   
Measurement Nominal   
Role Input   




















 Value Count Percent 
Standard Attributes Position 3   
Label <none>   
Type Numeric   
Format F8   
Measurement Nominal   
Role Input   
Valid Values 1 Less than 1 Year 10 16.7% 
2 1 to 5 Years 7 11.7% 
3 5 to 10 Years 13 21.7% 
4 10 to 15 Years 12 20.0% 
5 15 to 20 Years 10 16.7% 






 Value Count Percent 
Standard Attributes Position 5   
Label <none>   
Type Numeric   
Format F8.2   
Measurement Nominal   
Role Input   
Valid Values 1.00 Very Negative 8 13.3% 
2.00 Negative 13 21.7% 
3.00 Slightly Negative 2 3.3% 
4.00 Neutral 7 11.7% 
5.00 Satisfactory 7 11.7% 
6.00 Very Satisfactory 11 18.3% 
7.00 Excellent 12 20.0% 
 
SC2 
 Value Count Percent 
Standard Attributes Position 6   
Label <none>   
Type Numeric   
Format F8.2   
Measurement Nominal   
Role Input   
Valid Values 1.00 Very Negative 9 15.0% 
2.00 Negative 6 10.0% 
3.00 Slightly Negative 9 15.0% 
4.00 Neutral 9 15.0% 
5.00 Satisfactory 12 20.0% 
6.00 Very Satisfactory 7 11.7% 







 Value Count Percent 
Standard Attributes Position 8   
Label <none>   
Type Numeric   
Format F8.2   
Measurement Nominal   
Role Input   
Valid Values 1.00 Very Negative 11 18.3% 
2.00 Negative 5 8.3% 
3.00 Slightly Negative 9 15.0% 
4.00 Neutral 9 15.0% 
5.00 Satisfactory 7 11.7% 
6.00 Very Satisfactory 8 13.3% 
7.00 Excellent 11 18.3% 
SC3 
 Value Count Percent 
Standard Attributes Position 7   
Label <none>   
Type Numeric   
Format F8.2   
Measurement Nominal   
Role Input   
Valid Values 1.00 Very Negative 7 11.7% 
2.00 Negative 7 11.7% 
3.00 Slightly Negative 7 11.7% 
4.00 Neutral 11 18.3% 
5.00 Satisfactory 6 10.0% 
6.00 Very Satisfactory 14 23.3% 








 Value Count Percent 
Standard Attributes Position 10   
Label <none>   
Type Numeric   
Format F8.2   
Measurement Nominal   
Role Input   
Valid Values 1.00 Very Negative 11 18.3% 
2.00 Negative 9 15.0% 
3.00 Slightly Negative 8 13.3% 
4.00 Neutral 7 11.7% 
5.00 Satisfactory 5 8.3% 
6.00 Very Satisfactory 14 23.3% 
7.00 Excellent 6 10.0% 
SC5 
 Value Count Percent 
Standard Attributes Position 9   
Label <none>   
Type Numeric   
Format F8.2   
Measurement Nominal   
Role Input   
Valid Values 1.00 Very Negative 8 13.3% 
2.00 Negative 9 15.0% 
3.00 Slightly Negative 2 3.3% 
4.00 Neutral 9 15.0% 
5.00 Satisfactory 12 20.0% 
6.00 Very Satisfactory 7 11.7% 







 Value Count Percent 
Standard Attributes Position 12   
Label <none>   
Type Numeric   
Format F8.2   
Measurement Nominal   
Role Input   
Valid Values 1.00 Very Negative 6 10.0% 
2.00 Negative 10 16.7% 
3.00 Slightly Negative 10 16.7% 
4.00 Neutral 12 20.0% 
5.00 Satisfactory 8 13.3% 
6.00 Very Satisfactory 5 8.3% 









 Value Count Percent 
Standard Attributes Position 11   
Label <none>   
Type Numeric   
Format F8.2   
Measurement Nominal   
Role Input   
Valid Values 1.00 Very Negative 6 10.0% 
2.00 Negative 7 11.7% 
3.00 Slightly Negative 9 15.0% 
4.00 Neutral 8 13.3% 
5.00 Satisfactory 11 18.3% 
6.00 Very Satisfactory 7 11.7% 




 Value Count Percent 
Standard Attributes Position 13   
Label <none>   
Type Numeric   
Format F8.2   
Measurement Nominal   
Role Input   
Valid Values 1.00 Very Negative 12 20.0% 
2.00 Negative 7 11.7% 
3.00 Slightly Negative 11 18.3% 
4.00 Neutral 8 13.3% 
5.00 Satisfactory 10 16.7% 
6.00 Very Satisfactory 5 8.3% 
7.00 Excellent 7 11.7% 
 
RP5 
 Value Count Percent 
Standard Attributes Position 14   
Label <none>   
Type Numeric   
Format F8.2   
Measurement Nominal   
Role Input   
Valid Values 1.00 Very Negative 11 18.3% 
2.00 Negative 15 25.0% 
3.00 Slightly Negative 8 13.3% 
4.00 Neutral 5 8.3% 
5.00 Satisfactory 5 8.3% 
6.00 Very Satisfactory 10 16.7% 









 Value Count Percent 
Standard Attributes Position 15   
Label <none>   
Type Numeric   
Format F8.2   
Measurement Nominal   
Role Input   
Valid Values 1.00 Very Negative 8 13.3% 
2.00 Negative 6 10.0% 
3.00 Slightly Negative 9 15.0% 
4.00 Neutral 13 21.7% 
5.00 Satisfactory 7 11.7% 
6.00 Very Satisfactory 10 16.7% 
7.00 Excellent 7 11.7% 
 
OP2 
 Value Count Percent 
Standard Attributes Position 16   
Label <none>   
Type Numeric   
Format F8.2   
Measurement Nominal   
Role Input   
Valid Values 1.00 Very Negative 7 11.7% 
2.00 Negative 8 13.3% 
3.00 Slightly Negative 10 16.7% 
4.00 Neutral 13 21.7% 
5.00 Satisfactory 4 6.7% 
6.00 Very Satisfactory 12 20.0% 










 Value Count Percent 
Standard Attributes Position 17   
Label <none>   
Type Numeric   
Format F8.2   
Measurement Nominal   
Role Input   
Valid Values 1.00 Very Negative 10 16.7% 
2.00 Negative 9 15.0% 
3.00 Slightly Negative 4 6.7% 
4.00 Neutral 8 13.3% 
5.00 Satisfactory 7 11.7% 
6.00 Very Satisfactory 10 16.7% 
7.00 Excellent 12 20.0% 
 
OP4 
 Value Count Percent 
Standard Attributes Position 18   
Label <none>   
Type Numeric   
Format F8.2   
Measurement Nominal   
Role Input   
Valid Values 1.00 Very Negative 7 11.7% 
2.00 Negative 7 11.7% 
3.00 Slightly Negative 6 10.0% 
4.00 Neutral 6 10.0% 
5.00 Satisfactory 15 25.0% 
6.00 Very Satisfactory 11 18.3% 




 Value Count Percent 
Standard Attributes Position 19   
Label <none>   
Type Numeric   
Format F8.2   
Measurement Nominal   
Role Input   
Valid Values 1.00 Very Negative 8 13.3% 




4.00 Neutral 6 10.0% 




7.00 Excellent 9 15.0% 
 
OP6 
 Value Count Percent 
Standard Attributes Position 20   
Label <none>   
Type Numeric   
Format F8.2   
Measurement Nominal   
Role Input   
Valid Values 1.00 Very Negative 7 11.7% 




4.00 Neutral 10 16.7% 








 Value Count Percent 
Standard Attributes Position 21   
Label <none>   
Type Numeric   
Format F8.2   
Measurement Nominal   
Role Input   
Valid Values 1.00 Very Negative 9 15.0% 




4.00 Neutral 10 16.7% 
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